The first patient to receive Coley Fluid was a sixteen-year-old boy with a massive abdominal tumor. Every few days, Coley injected his fluid directly into the tumor mass and produced the symptoms of an infectious disease, but did not produce the disease itself. On each injection, there was a dramatic rise in body temperature and chills. The tumour gradually diminished in size. By May 1893, after four months of intensive treatment, the tumour was a fifth its original size. By August, the remains of the growth were barely perceptible. The boy received no further anticancer treatment and remained in good health until he died of a heart attack 26 years later.

Coley published his results and by the turn of the century 42 physicians from Europe and North America had reported cases of cancer that had been successfully treated with Coley Fluid. Coley Fluid became a mainstream cancer treatment and was successfully used in the treatment of most types of cancer. Until his death in 1936, Coley was the head of the bone tumor department at Memorial Hospital in New York City where he treated thousands of bone cancer patients with his fluid. In the United States the pharmaceutical company Parke Davis manufactured Coley Fluid until 1951.

The historical results of Coley Fluid therapy are difficult to compare with modern results. Even so, every published study has reached the same conclusion: Coley Fluid therapy is as good, or better, than modern therapies. However, there were many different formulations of Coley Fluid that varied greatly in effectiveness, and there were many different treatment protocols that also varied greatly in effectiveness. The company believes its Coley Fluid formulation and treatment protocol will be more effective than current therapies for a wide range of cancers.

Click here for book excerpt - “Coley” from Spontaneous Regression: Cancer and the Immune System, by Donald H. MacAdam.